GlyTherix signed the HOA with Cyclowest

GlyTherix signed the HOA with Cyclowest

We are pleased to work with the Cyclowest team, Nat Lenzo and Thomas Tuchyna to bring new targeted radiotherapies to patients. Cyclowest started to produce Zirconium-89 with a plan to obtain TGA licensing for several Zr-89 products over the next 12 months. GlyTherix...
2024 BioShares Biotech Summit

2024 BioShares Biotech Summit

We are pleased to be attending the upcoming summit in Fremantle this coming Friday and Saturday. Looking forward to discussing GlyTherix Ltd’s targeted radiotherapy program which holds tremendous potential to enhance treatment efficacy while minimizing adverse...
GlyTherix Roadshow

GlyTherix Roadshow

Meet with targeted radiotherapy company GlyTherix Ltd in Boston and New York. Next week Brad Walsh, CEO and David Burdis, CFO will be joining with their advisors Atoll Financial Group for a roadshow in Boston Monday May 6 and Tuesday May 7 followed by New York May 8...
GlyTherix US Expansion

GlyTherix US Expansion

GlyTherix Ltd is pleased to announce Alan Harris MD PhD has taken an expanded role as a Strategic and Scientific Advisor to assist the company increase its current US footprint including retention of key US-based personnel. He will work closely with GlyTherix’s Dr...